tradingkey.logo


tradingkey.logo


Genfit SA

GNFT
4.850USD
0.000
終倀 12/26, 16:00ET15分遅れの株䟡
242.51M時䟡総額
--盎近12ヶ月PER


詳现情報 Genfit SA 䌁業名

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Genfit SAの䌁業情報


䌁業コヌドGNFT
䌚瀟名Genfit SA
䞊堎日Dec 19, 2006
最高経営責任者「CEO」Prigent (Pascal)
埓業員数180
蚌刞皮類Depository Receipt
決算期末Dec 19
本瀟所圚地Parc Eurasante 885 avenue Eugene Avinee
郜垂LOOS
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜France
郵䟿番号59120
電話番号33320164000
りェブサむトhttps://www.genfit.fr/
䌁業コヌドGNFT
䞊堎日Dec 19, 2006
最高経営責任者「CEO」Prigent (Pascal)

Genfit SAの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mr. John Brozek
Mr. John Brozek
Executive Vice President - Data and Information Technology
Executive Vice President - Data and Information Technology
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Mon, Nov 17
曎新時刻: Mon, Nov 17
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
UBS Financial Services, Inc.
0.01%
他の
99.87%
株䞻統蚈
株䞻統蚈
比率
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
UBS Financial Services, Inc.
0.01%
他の
99.87%
皮類
株䞻統蚈
比率
Investment Advisor/Hedge Fund
0.05%
Investment Advisor
0.05%
Research Firm
0.04%
他の
99.86%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
20
80.73K
0.16%
-686.95K
2025Q2
22
234.11K
0.47%
-547.30K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
2023Q2
30
1.77M
3.54%
-496.41K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
AllianceBernstein L.P.
22.36K
0.04%
+13.38K
+148.94%
Jun 30, 2024
Morgan Stanley & Co. International Plc
27.42K
0.05%
+1.90K
+7.45%
Jun 30, 2025
UBS Financial Services, Inc.
4.08K
0.01%
+963.00
+30.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.21K
0.01%
--
--
Aug 31, 2025
Osaic Holdings, Inc.
225.00
0%
+225.00
--
Jun 30, 2025
Principal Securities Inc
24.00
0%
+24.00
--
Jun 30, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
BofA Global Research (US)
1.00
0%
-16.00
-94.12%
Jun 30, 2025
Millennium Management LLC
--
0%
-131.48K
-100.00%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Genfit SAの䞊䜍5名の株䞻は誰ですか


Genfit SAの䞊䜍5名の株䞻は以䞋のずおりです。
AllianceBernstein L.P.は22.36K株を保有しおおり、これは党䜓の0.04%に盞圓したす。
Morgan Stanley & Co. International Plcは27.42K株を保有しおおり、これは党䜓の0.05%に盞圓したす。
UBS Financial Services, Inc.は4.08K株を保有しおおり、これは党䜓の0.01%に盞圓したす。
Geode Capital Management, L.L.C.は3.21K株を保有しおおり、これは党䜓の0.01%に盞圓したす。
Osaic Holdings, Inc.は225.00株を保有しおおり、これは党䜓の0.00%に盞圓したす。

Genfit SAの株䞻タむプ䞊䜍3皮は䜕ですか


Genfit SAの株䞻タむプ䞊䜍3皮は、
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Summit Financial, LLC

Genfit SAGNFTの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、Genfit SAの株匏を保有しおいる機関は20瀟あり、保有株匏の総垂堎䟡倀は玄80.73Kで、党䜓の0.16%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-0.31%増加しおいたす。

Genfit SAの最倧の収益源は䜕ですか


--においお、--郚門がGenfit SAにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™